Long-term data suggests longer treatments with Viaskin Peanut improve peanut tolerance.
News & Analysis: DBV Technologies
Traders cheered after the company announced the pricing details of a stock offering.
Find out why these stocks stood out on a down day for the market.
Shares collapse after the company provides investors with an unfavorable regulatory update.
The FDA is "supporting" the biotech submitting a marketing application for Viaskin Peanut, but how strong that support is remains to be seen.
One biotech's phase 3 failure benefits its competitor.
DBV Technologies is raising more than $244 million to develop therapies for peanut and milk allergies.